PRESS RELEASES

October 10, 2025
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Learn More
September 4, 2025
Orbital Therapeutics Appoints Accomplished Drug Developer Adam Raff, M.D., Ph.D., as Senior Vice President, Clinical Development
Learn More
July 22, 2025
Orbital Therapeutics Presents Non-Human Primate Data for In Vivo CAR-T Therapy with Potential Best-in-Class Profile for Autoimmune Disease
Learn More
March 6, 2025
Orbital Therapeutics Appoints Geno Germano, Biopharma Veteran, to its Board of Directors
Learn More
September 5, 2024
Orbital Therapeutics Appoints Anna Dixon as Senior Vice President, Human Resources
Learn More
September 3, 2024
Orbital Therapeutics Appoints Veteran Biopharma Leader, Ron Philip, as Chief Executive Officer
Learn More
April 26, 2023
Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines
Learn More
September 7, 2022
Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines
Learn More

see all press releases

Awards and Recognition

2024 Start-Up of the Year Finalist
2024 Inno Blazer -
Early Stage Biotech Category
2023 Finalist -
BostInno’s Startups to Watch
BioSpace's NextGen Class of 2024
Learn More
2023 Endpoints 11
Learn More
BioTech Breakthrough Awards – 2023 BioTech Startup of the Year Medicines
© 2025 Orbital Therapeutics  •  Privacy Policy  •  Terms of Use
 
 

This links to an external website.

Continue